CA80401L3083
© Newsfile
17.03.2023
MSCL
LISTED
TSX
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
News Preview
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and SummitToronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered...
Themefolio
Profiler
Peergroup
© Newsfile
10.03.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy
News Preview
Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce additional results fr...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Newsfile
06.02.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
News Preview
- 40% increase in muscle size compared to control mice - 25% increase in muscle force, approaching levels seen in normal miceToronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regener...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Newsfile
03.01.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Development Candidate
News Preview
- SAT-3153 Designated for pre-IND Studies -Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging,...
Themefolio
Profiler
Peergroup
© Newsfile
23.11.2022
MSCL
LISTED
TSX
Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights
News Preview
Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights fo...
Themefolio
Profiler
Peergroup
© Newsfile
03.11.2022
MSCL
LISTED
TSX
Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development
News Preview
-Proof of concept studies to be completed by YE-Toronto, Ontario--(Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce t...
Themefolio
Profiler
Peergroup
© Newsfile
11.10.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting
News Preview
- Advancements on the Company's evaluation of potential new disease indicationToronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dys...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces the Grant of Stock Options
News Preview
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the "Board") has...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd.
News Preview
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), is pleased to announce that its wholly owned subsidiary Amphotericin B Technologies Inc. ("AmpB Tech") and NW PharmaTech Ltd. ("NWPT") have today established a joint venture company, NW Micelle Therapeutics Inc. ("NWMT"),...
Themefolio
Profiler
Peergroup
© Newsfile
06.10.2022
MSCL
LISTED
TSX
Satellos Bioscience Announces OTCQB Listing in the United States
News Preview
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that its common shar...
Themefolio
Profiler
Peergroup
© Newsfile
28.09.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer
News Preview
Toronto, Ontario--(Newsfile Corp. - September 28, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that its board of directors (the "Board") has appointed Philip Lambert, P...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
13.09.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Closing of Offering of Units
News Preview
Toronto, Ontario--(Newsfile Corp. - September 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the closing of its previously announced public offering (the "Offering")...
Themefolio
Profiler
Peergroup
© Newsfile
07.09.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces the Filing of Final Short Form Prospectus for Proposed Offering of Units
News Preview
Toronto, Ontario--(Newsfile Corp. - September 7, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed its final short form prospectus (the "Prospectus") with the sec...
Themefolio
Profiler
Peergroup
© Newsfile
31.08.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Pricing of Proposed Offering of Units
News Preview
Toronto, Ontario--(Newsfile Corp. - August 30, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has priced its previously announced proposed offering (the "Offering") of u...
Themefolio
Profiler
Peergroup
© Newsfile
30.08.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of Units
News Preview
Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed an amended and restated preliminary short form prospectus (the "A...
Themefolio
Profiler
Peergroup
© Newsfile
30.08.2022
MSCL
LISTED
TSX
Satellos Bioscience Reports Q2 2022 Financials and Operating Results
News Preview
Toronto, Ontario--(Newsfile Corp. - August 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, filed its financial and operating results on 29 August 2022 for the quarter ended June 30, 2022...
Themefolio
Profiler
Peergroup
© Newsfile
25.07.2022
MSCL
LISTED
TSX
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Awarded Significant Grant from the Canadian Institutes of Health Research
News Preview
Toronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been...
Themefolio
Profiler
Peergroup
© Newsfile
13.07.2022
MSCL
LISTED
TSX
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature Communications
News Preview
Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has had...
Themefolio
Profiler
Peergroup
© Newsfile
11.07.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Proposed Offering of Units
News Preview
Toronto, Ontario--(Newsfile Corp. - July 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus with the securities regulatory...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2022
MSCL
LISTED
TSX
Satellos Bioscience Announces In-Licensing of New Patent Application
News Preview
Toronto, Ontario--(Newsfile Corp. - June 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has licensed a provisional patent application, recently filed with the United...
Themefolio
Profiler
Peergroup
© Newsfile
22.06.2022
MSCL
LISTED
TSX
Satellos Bioscience Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal Society
News Preview
Toronto, Ontario--(Newsfile Corp. - June 22, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2022
MSCL
LISTED
TSX
Satellos Bioscience Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 Grant
News Preview
Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been named one...
Themefolio
Profiler
Peergroup
© Newsfile
14.06.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. to Present at Bio International Convention 2022
News Preview
Dr. Ryan Mitchell, PhD and Director of Business Development to highlight Satellos’ novel muscle regeneration technology on June 15Toronto, Ontario--(Newsfile Corp. - June 14, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way deg...
Themefolio
Profiler
Peergroup
© Newsfile
31.05.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces First Quarter Financial Results and Operational Highlights
News Preview
Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutic drugs that change the way degenerative muscle diseases are treated, today announced its unaudited financial results and operational highlights for the quarter ended...
Themefolio
Profiler
Peergroup
© Newsfile
30.04.2022
MSCL
LISTED
TSX
Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights
News Preview
Toronto, Ontario--(Newsfile Corp. - April 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ending December 31, 20...
Themefolio
Profiler
Peergroup
© Newsfile
26.04.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
News Preview
Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos Bioscience was invited to present at the 2022 Bloom Burton...
Themefolio
Profiler
Peergroup
© Newsfile
21.04.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. to Present Game Changing Science at Upcoming European Molecular Biology Organization Workshop
News Preview
Ryan Mitchell, PhD and Director of Business Development to highlight advancements with Satellos' novel muscle regeneration technology on April 25-26 in Gouvieux, FranceToronto, Ontario--(Newsfile Corp. - April 21, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing the...
Themefolio
Profiler
Peergroup
© Newsfile
29.03.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc.'s CSO to Present Game Changing Science During March 30th Drug Discovery News Webinar
News Preview
Michael Rudnicki, PhD and Chief Scientific Officer to highlight new advancements with Satellos' novel muscle regeneration technology on March 30Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), a biotechnology company aimed at developing therapeutics that change the way degenerative muscle dis...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2022
MSCL
LISTED
TSX
Satellos Bioscience Provides Update on Novel Regenerative Drug Candidates
News Preview
Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a biotechnology company developing therapeutics that have the potential to transform the way degenerative muscle diseases are treated, today announced progress in designing and developing the world's first small molecule drug c...
Themefolio
Profiler
Peergroup
© Newsfile
11.03.2022
MSCL
LISTED
TSX
Satellos Bioscience Provides Update on Joint Development Initiative with NW PharmaTech Limited
News Preview
Toronto, Ontario--(Newsfile Corp. - March 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a biotechnology company developing therapeutics that have the potential to transform the way degenerative muscle diseases are treated, today announced progress towards monetizing its novel and proprietary oral pharmaceutical tr...
Themefolio
Profiler
Peergroup
© Newsfile
10.03.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. to Present Game Changing Science at Insights in Research Investor Summit and MDA Clinical & Scientific Conference 2022
News Preview
Ryan Mitchell, PhD and Director of Business Development to highlight new advancements with Satellos' novel muscle regeneration technologyToronto, Ontario--(Newsfile Corp. - March 10, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way d...
Themefolio
Profiler
Peergroup
© Newsfile
10.02.2022
MSCL
LISTED
TSX
Satellos Bioscience to Participate at BIO CEO & Investor Conference 2022
News Preview
Toronto, Ontario--(Newsfile Corp. - February 10, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, President and CEO, will present at the BIO CEO & Investor...
Themefolio
Profiler
Peergroup
© Newsfile
24.01.2022
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces CEO Letter to Shareholders
News Preview
Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - Satellos Bioscience Inc. (TSXV: MSCL)To our shareholders,Satellos Bioscience Inc. (TSXV: MSCL) (OTC: MSCLF) ("Satellos") is at the forefront of bold new science. Our research team has made seminal and, to many, game changing discoveries into the body's regenerative processes. Based o...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2022
MSCL
LISTED
TSX
Satellos Bioscience to Participate at Biotech Showcase(TM) Virtual 2022
News Preview
Toronto, Ontario--(Newsfile Corp. - January 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, President and CEO, will present virtually at the Biotech Showca...
Themefolio
Profiler
Peergroup
© Newsfile
16.12.2021
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular Dystrophies
News Preview
Collaborative research program will assess potential for Satellos drug candidates to treat rare dystrophic disease indicationsToronto, Ontario--(Newsfile Corp. - December 16, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation") is pleased to announce that it has entered into a scientific research agreement (the "Agreement...
Themefolio
Profiler
Peergroup
© Newsfile
06.12.2021
MSCL
LISTED
TSX
Satellos Bioscience Announces New Board Appointments
News Preview
Satellos welcomes new board members to strengthen its pharmaceutical and North American capital markets expertise in support of its value-build strategyToronto, Ontario--(Newsfile Corp. - December 6, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that cha...
Themefolio
Profiler
Peergroup
© Newsfile
29.11.2021
MSCL
LISTED
TSX
Satellos Bioscience Reports Third Quarter 2021 Financial Results and Operational Highlights
News Preview
Satellos positioned to pursue the development of first-in-class regenerative therapeutic treatments for degenerative muscle diseases.Toronto, Ontario--(Newsfile Corp. - November 29, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company, formerly known as iCo Therapeutics Inc. ("iCo"), aimed at...
Themefolio
Profiler
Peergroup
© Newsfile
27.10.2021
MSCL
LISTED
TSX
Satellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations Services
News Preview
Toronto, Ontario--(Newsfile Corp. - October 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation") is pleased to announce that it has entered into an investor relations agreement (the "Investor Relations Agreement") with BND Projects Inc. ("BND") whereby BND will provide strategic investor relations services. BND will a...
Themefolio
Profiler
Peergroup
© Newsfile
17.09.2021
MSCL
LISTED
TSX
Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration
News Preview
Toronto, Ontario--(Newsfile Corp. - September 17, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) (Satellos" or the "Company"), a regenerative medicine company focused on the treatment of Duchenne muscular dystrophy and other degenerative or muscle wasting disorders, is pleased to announce that the Company's board of directors has appointed J. Robert...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
